Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
well given it was delisted, shares were frozen, and it's a penny stock...i gotta think that's the best valuation. what are you thinking?
Anyone else see this:
http://investorshub.advfn.com/boards/profiles.aspx?user=307798
Is this Gerald the CEO? Shady....
Ties between GDNF, MANF and Hermo Pharma
(1) Hermo Pharma is currently working on CDNF, another protein in the trophic factors family
(2) Hermo Pharma is funded by VCs and has $700k in MJFF grants
(3) World reknown Professor Mart Saarma is on the Scientific Advisory Board of Hermo Pharma:http://www.hermopharma.com/about-us/scientific-advisory-board
(4) Mart Saarma was intimately involved with GDNF and is keenly aware of the entire trophic factors family of proteins
(5) Mart Saarma has worked with Professor Steven Gill from Bristol Univ who is now leading GDNF in phase II trials. Prof Gill has developed a new infusion device that allows for much better and more efficient delivery methods: http://www.wobblywilliams.com/gdnf.html
(6) Mart Saarma and Hermo Pharma sued AMBS, challenging their patents in court in Europe on the grounds that their MANF patents cause "an undue burden on anyone trying to test MANF because it covers anything with a 90% homology (ie similarity) to MANF:"; AMBS's patents were upheld in court:
http://m.seekingalpha.com/instablog/167303-jonathan-verenger/1348791-exciting-field-in-cure-for-parkinson-s
(7) It has been shown that MANF performs better than CDNF and GDNF in pre clinical trials.
(8) GDNF was owned by a company purchased for $250 Million during pre-clinical trials.
(9) Neurturin is another trophic factor in phase I that has received $150 Million in funding.
All of the above reasons are why I'm so bullish on this company and why I think there will be much higher prices in store. I believe that a partnership/licensing deal is the most likely outcome. I don't expect a buyout. I think someone will come in initially with a $15 Million funding as well as a licensing deal. The patents that AMBS owns and that were upheld in court are far too valuable. Anyone that wants to work on MANF has to come through AMBS. If anyone alters any of the other proteins (GDNF, CDNF, etc) such that the altered protein has a 90% homology (i.e., similarity) to MANF, they have to come to MANF and license it. That is unbelievably valuable. That is why I refuse to sell this stock and why I think anyone that is not in the stock and anyone looking to flip it will come to regret it.
References on Mart Saarma
http://www.google.com/search?client=safari&rls=en&q=mart+saarma+gdnf&ie=UTF-8&oe=UTF-8
Has anyone considered the possibility that the drop last Thursday was caused in part by people that got wind of the CUSIP change occurring and shares being locked up? If that's the case the selloff tomorrow could be mild and could cause a huge run up after people realize there isn't a big selloff. Will be fun to watch tomorrow and Friday as we head into the conference.
I don't see that much of a drop...in fact, if the dip doesn't violate the lows from today then that is EXTREMELY bullish and sets up for a big move into and after the conference. I think this ultimately gets a $100+ Million market cap.
Looks like Tomorrow is the Day. I received a notice from TD Ameritrade:
"The depository is now listing tomorrow, 1/3/12, for when AMBS is expected to allocate. Your position should be updated tomorrow morning. "
This is just a guess but I think there is a sharp selloff but most importantly I think it is the last chance anyone gets to buy the stock cheap. I think people that are impatient are itching to sell the stock when they get a chance and it will give people one last chance to buy cheaply before it rockets higher.
You guys know that I'm officially about as bullish as it gets on this stock. I have been in it since $0.03 down to $0.018. I think it could dip to the $0.07 to $0.08 level at which point I would highly recommend to anyone not in the stock to get in. I will be using this as an opportunity to add shares if it gets down there.
My Thesis on Why AMBS is one of the Cheapest Stocks in the Market
(1) Hermo Pharma is currently working on CDNF, another protein in the trophic factors family
(2) Hermo Pharma is funded by VCs and has $700k in MJFF grants
(3) World reknown Professor Mart Saarma is on the Scientific Advisory Board of Hermo Pharma:http://www.hermopharma.com/about-us/scientific-advisory-board
(4) Mart Saarma was intimately involved with GDNF and is keenly aware of the entire trophic factors family of proteins
(5) Mart Saarma has worked with Professor Steven Gill from Bristol Univ who is now leading GDNF in phase II trials. Prof Gill has developed a new infusion device that allows for much better and more efficient delivery methods: http://www.wobblywilliams.com/gdnf.html
(6) Mart Saarma and Hermo Pharma sued AMBS, challenging their patents in court in Europe on the grounds that their MANF patents cause "an undue burden on anyone trying to test MANF because it covers anything with a 90% homology (ie similarity) to MANF:"; AMBS's patents were upheld in court:
http://m.seekingalpha.com/instablog/167303-jonathan-verenger/1348791-exciting-field-in-cure-for-parkinson-s
(7) It has been shown that MANF performs better than CDNF and GDNF in pre clinical trials.
(8) GDNF was owned by a company purchased for $250 Million during pre-clinical trials.
(9) Neurturin is another trophic factor in phase I that has received $150 Million in funding.
All of the above reasons are why I'm so bullish on this company and why I think there will be much higher prices in store. I believe that a partnership/licensing deal is the most likely outcome. I don't expect a buyout. I think someone will come in initially with a $15 Million funding offer as well as a licensing deal. The patents that AMBS owns and that were upheld in court are far too valuable. Anyone that wants to work on MANF has to come through AMBS. If anyone alters any of the other proteins (GDNF, CDNF, etc) such that the altered protein has a 90% homology (i.e., similarity) to MANF, they have to come to MANF and license it. That is unbelievably valuable. That is why I refuse to sell this stock and why I think anyone that is not in the stock and anyone looking to flip it will come to regret it.
I'm not trying to undermine anything. It's just my own personal belief. Let's say we get a nasty selloff...I think if it happens within a few days/weeks it will be back to the prior highs and higher. So to me it doesn't really matter because I'm patient and will see this through. If it dips to $0.08 or lower I will add more shares.
We will see next week just how good the data is. I believe it is going to continue to show promise relative to the other neurotrophic factors and having Dr. Rubinfeld as a speaker will do wonders in sealing a partnership/license deal. That's what matters more to me than a temporary drop which I think is inevitable. I believe we will see a drop by the close before whenever the CUSIP change goes into effect at the brokers and then it will gap lower. There could be some panic selling, but again, this will be the last chance for people on the sidelines to get in at cheap prices.
vg - i'm not a cj wannabe at all man. i've never tried to deceive anyone...i actually think people need to have a little more integrity
i'm long this bad boy and have been for a while. just realistic that there will be a short term nasty selloff when the shares hit the brokers. i think a 50% drop is inevitable. but you know what? the bounces have been getting faster and faster and my guess is it goes right back up to the old highs (whatever they ultimately get to) before the CUSIP transfer is put into place.
all along i have said that this is a $100+ Million company because of the patent protection it has, the big pharma advisors on board, and the positive comparisons to GDNF/Neurturing, both of which had over $150 Million in funding at similar stages during testing.
i will not be bailing on my shares but rather i'll be picking up shares if they sell off after the CUSIP conversion goes through. should be a volatile couple of days when that happens.
Yeah that's why I think there will be a big selloff. The average person that is investing in this stock is holding it for probably a couple of days unlike myself. I understand the story and believe it eventually gets to $0.40+.
I will be using the cash I have to buy up shares after the dust settles. I'm not really sure where it bottoms at but I think a few logical places is $0.087, $0.06 and $0.041.
No you can't. You can not trade any shares purchased before last Friday.
That's not true. Ameritrade has a freeze on selling the old shares.
There will be a very sharp selloff when the shares are transferred. This is just a guess but I think this happens and it is the last chance anyone gets to buy the stock cheap. I think a lot of people with the "old" shares are itching to sell the stock when they get a chance and it will give people one last chance to buy cheaply before it rockets higher. But you better be really quick with the buy button when it happens.
You guys know that I'm officially about as bullish as it gets on this stock. I have been in it since $0.03 down to $0.018. I think it could dip all the way down to the $0.09 level at which point I would highly recommend to anyone not in the stock to get in. If this happens I will be using it as an opportunity to add shares.
My Thesis on Why AMBS is the Cheapest Stock in the Market
(1) Hermo Pharma is currently working on CDNF, another protein in the trophic factors family
(2) Hermo Pharma is funded by VCs and has $700k in MJFF grants
(3) World reknown Professor Mart Saarma is on the Scientific Advisory Board of Hermo Pharma:http://www.hermopharma.com/about-us/scientific-advisory-board
(4) Mart Saarma was intimately involved with GDNF and is keenly aware of the entire trophic factors family of proteins
(5) Mart Saarma has worked with Professor Steven Gill from Bristol Univ who is now leading GDNF in phase II trials. Prof Gill has developed a new infusion device that allows for much better and more efficient delivery methods: http://www.wobblywilliams.com/gdnf.html
(6) Mart Saarma and Hermo Pharma sued AMBS, challenging their patents in court in Europe on the grounds that their MANF patents cause "an undue burden on anyone trying to test MANF because it covers anything with a 90% homology (ie similarity) to MANF:"; AMBS's patents were upheld in court:
http://m.seekingalpha.com/instablog/167303-jonathan-verenger/1348791-exciting-field-in-cure-for-parkinson-s
(7) It has been shown that MANF performs better than CDNF and GDNF in pre clinical trials.
(8) GDNF was owned by a company purchased for $250 Million during pre-clinical trials.
(9) Neurturin is another trophic factor in phase I that has received $150 Million in funding.
All of the above reasons are why I'm so bullish on this company and why I think there will be much higher prices in store. I believe that a partnership/licensing deal is the most likely outcome. I don't expect a buyout. I think someone will come in initially with a $15 Million funding as well as a licensing deal. The patents that AMBS owns and that were upheld in court are far too valuable. Anyone that wants to work on MANF has to come through AMBS. If anyone alters any of the other proteins (GDNF, CDNF, etc) such that the altered protein has a 90% homology (i.e., similarity) to MANF, they have to come to MANF and license it. That is unbelievably valuable. That is why I refuse to sell this stock and why I think anyone that is not in the stock and anyone looking to flip it will come to regret it.
Can you sell your shares?
here is my take...there are a lot doubters on this stock that will sell for a variety of reasons and those doubters will be left sitting on the sidelines watching it go higher and higher and kicking themselves for having not been patient.
I believe a short/quick selloff is coming when shares are transferred. This is just a guess but I think this happens and it is the last chance anyone gets to buy the stock cheap. I think people that are impatient are itching to sell the stock when they get a chance and it will give people one last chance to buy cheaply before it rockets higher.
You guys know that I'm officially about as bullish as it gets on this stock. I have been in it since $0.03 down to $0.018. I think it could dip to the $0.09 level at which point I would highly recommend to anyone not in the stock to get in. I will be using this as an opportunity to add shares.
My Thesis on Why AMBS is the Cheapest Stock in the Market
(1) Hermo Pharma is currently working on CDNF, another protein in the trophic factors family
(2) Hermo Pharma is funded by VCs and has $700k in MJFF grants
(3) World reknown Professor Mart Saarma is on the Scientific Advisory Board of Hermo Pharma:http://www.hermopharma.com/about-us/scientific-advisory-board
(4) Mart Saarma was intimately involved with GDNF and is keenly aware of the entire trophic factors family of proteins
(5) Mart Saarma has worked with Professor Steven Gill from Bristol Univ who is now leading GDNF in phase II trials. Prof Gill has developed a new infusion device that allows for much better and more efficient delivery methods: http://www.wobblywilliams.com/gdnf.html
(6) Mart Saarma and Hermo Pharma sued AMBS, challenging their patents in court in Europe on the grounds that their MANF patents cause "an undue burden on anyone trying to test MANF because it covers anything with a 90% homology (ie similarity) to MANF:"; AMBS's patents were upheld in court:
http://m.seekingalpha.com/instablog/167303-jonathan-verenger/1348791-exciting-field-in-cure-for-parkinson-s
(7) It has been shown that MANF performs better than CDNF and GDNF in pre clinical trials.
(8) GDNF was owned by a company purchased for $250 Million during pre-clinical trials.
(9) Neurturin is another trophic factor in phase I that has received $150 Million in funding.
All of the above reasons are why I'm so bullish on this company and why I think there will be much higher prices in store. I believe that a partnership/licensing deal is the most likely outcome. I don't expect a buyout. I think someone will come in initially with a $15 Million funding as well as a licensing deal. The patents that AMBS owns and that were upheld in court are far too valuable. Anyone that wants to work on MANF has to come through AMBS. If anyone alters any of the other proteins (GDNF, CDNF, etc) such that the altered protein has a 90% homology (i.e., similarity) to MANF, they have to come to MANF and license it. That is unbelievably valuable. That is why I refuse to sell this stock and why I think anyone that is not in the stock and anyone looking to flip it will come to regret it.
FYI DELL never traded at pennies. You have to adjust for splits:
http://finance.yahoo.com/q/hp?s=DELL&d=0&e=1&f=2013&g=d&a=7&b=17&c=1988&z=66&y=6138
By the way, the 90% homology issue that was held up in court might suggest that any alteration of GDNF and CDNF and Neurturin could infringe on AMBS's patents of MANF. These proteins are all similar in some sense yet MANF has been shown to be much more successful than GDNF, and researchers might feel compelled to alter GDNF in a way that it becomes more like MANF and the 90% homology factor (i.e., if anything has a 90% similarity to MANF) could cause researchers to have to come to AMBS to get a license to work on it.
When you get a chance read this article closer:
http://seekingalpha.com/instablog/167303-jonathan-verenger/1348791-exciting-field-in-cure-for-parkinson-s
I think this part is very important:
"Their patent covers all sequences with 90% homology to MANF (182 amino acid protein --> variation in 18 amino acid residues allowed, 20 options for each position --> you do the math; the result is an astronomical number of variants!). According to the patent law this causes "an undue burden" to anyone who would like to test these variants for activity. This is the explanation why we have challenged the EPO granted patent on MANF for Amarantus."
I would not take this issue lightly. I think it is what makes this protein so valuable and why I think a market cap of $30 MIllion is laughable.
FD: I have been long since $0.03 all the way down to $0.018. My average is around $0.025 or so. However, I think this should be worth at least $100 Million right now. That would be based on a significant discount to the purchase price of GDNF at the same stage of testing that MANF is in (i.e., pre clinical) and what was spent so far on Neurturin. I think there is a potential that we could see AMBS climb to $1.00, though, especially if the bull market in biotech stocks continues which I see no reason why it won't.
I'm not sure when the transfer will occur but I do think that will cause a temporary drop. The drops are becoming shallower and shallower and the rebounds are coming much quicker. I think this will be the last opportunity for anyone looking to get in. I have no idea what the drop would go down to but the two levels I'm watching to add are $0.10 and $0.087.
Either way, AMBS is an EPIC Stock. EPIC Stocks can be found once every 5 years or so. They go up 100 to 300 times their value over the span of 6 to 12 months. Bashers come on board and try to knock it down only to watch it put in higher lows throughout the run and leave people without patience sitting in awe as the stock barrels higher. People will try to spin wild webs of fancy like dilution, conspiracy theories as to why they drop suddenly every once in a while, etc. Yet after each minor blip it continues higher. Anyone that sells is left kicking themselves. That's what EPIC stocks do.
There are far too many positives here and the valuation is still ridiculously low. Here is a list of just some of the positives (First few are showing the ties amongst the other trophic factors, CDNF and GDNF and Neurturin and how it proves that the value of MANF is multiples higher than $30 Million which is what AMBS's market cap is):
(1) Hermo Pharma is currently working on CDNF, another protein in the trophic factors family
(2) Hermo Pharma is funded by VCs and has $700k in MJFF grants
(3) World renown Professor Mart Saarma is on the Scientific Advisory Board of Hermo Pharma:http://www.hermopharma.com/about-us/scientific-advisory-board
(4) Mart Saarma was intimately involved with GDNF and is keenly aware of the entire trophic factors family of proteins
(5) Mart Saarma has worked with Professor Steven Gill from Bristol Univ who is now leading GDNF in phase II trials. Prof Gill has developed a new infusion device that allows for much better and more efficient delivery methods: http://www.wobblywilliams.com/gdnf.html
(6) Mart Saarma and Hermo Pharma sued AMBS, challenging their patents in court in Europe on the grounds that their MANF patents cause "an undue burden on anyone trying to test MANF because it covers anything with a 90% homology (ie similarity) to MANF:"; AMBS's patents were upheld in court:
http://m.seekingalpha.com/instablog/167303-jonathan-verenger/1348791-exciting-field-in-cure-for-parkinson-s
(7) It has been shown that MANF performs better than CDNF and GDNF in pre clinical trials.
(8) GDNF was owned by a company purchased for $250 Million during pre-clinical trials.
(9) Neurturin is another trophic factor in phase I that has received $150 Million in funding.
(10) World renown Joseph Rubinfeld, co-founder of Amgen, has stated that MANF could be the biggest success he has ever seen and that if AMBS pursues an Orphan Drug strategy it could be a blockbuster drug.
I think there will be a bit of pressure on the stock when the old shares are transferred but I think it's the last chance that anyone sitting on the sidelines gets to get back into the stock below $0.10.
The only reason I'm saying it might is because I see a lot of people posting about how they're calling brokers trying to sell. I think you will see a wave of selling that will bring it down to the prior old highs of around $0.087ish but good luck getting shares when it pulls back. It will bounce hard and fast.
For me, I'm holding on to my shares until it hits $0.40 at which point I will sell a chunk and let the rest ride.
Selloff coming when shares are transferred. This is just a guess but I think this happens and it is the last chance anyone gets to buy the stock cheap. I think people that are impatient are itching to sell the stock when they get a chance and it will give people one last chance to buy cheaply before it rockets higher.
You guys know that I'm officially about as bullish as it gets on this stock. I have been in it since $0.03 down to $0.018. I think it could dip to the $0.09 level at which point I would highly recommend to anyone not in the stock to get in. I will be using this as an opportunity to add shares.
My Thesis on Why AMBS is the Cheapest Stock in the Market
(1) Hermo Pharma is currently working on CDNF, another protein in the trophic factors family
(2) Hermo Pharma is funded by VCs and has $700k in MJFF grants
(3) World reknown Professor Mart Saarma is on the Scientific Advisory Board of Hermo Pharma:http://www.hermopharma.com/about-us/scientific-advisory-board
(4) Mart Saarma was intimately involved with GDNF and is keenly aware of the entire trophic factors family of proteins
(5) Mart Saarma has worked with Professor Steven Gill from Bristol Univ who is now leading GDNF in phase II trials. Prof Gill has developed a new infusion device that allows for much better and more efficient delivery methods: http://www.wobblywilliams.com/gdnf.html
(6) Mart Saarma and Hermo Pharma sued AMBS, challenging their patents in court in Europe on the grounds that their MANF patents cause "an undue burden on anyone trying to test MANF because it covers anything with a 90% homology (ie similarity) to MANF:"; AMBS's patents were upheld in court:
http://m.seekingalpha.com/instablog/167303-jonathan-verenger/1348791-exciting-field-in-cure-for-parkinson-s
(7) It has been shown that MANF performs better than CDNF and GDNF in pre clinical trials.
(8) GDNF was owned by a company purchased for $250 Million during pre-clinical trials.
(9) Neurturin is another trophic factor in phase I that has received $150 Million in funding.
All of the above reasons are why I'm so bullish on this company and why I think there will be much higher prices in store. I believe that a partnership/licensing deal is the most likely outcome. I don't expect a buyout. I think someone will come in initially with a $15 Million funding as well as a licensing deal. The patents that AMBS owns and that were upheld in court are far too valuable. Anyone that wants to work on MANF has to come through AMBS. If anyone alters any of the other proteins (GDNF, CDNF, etc) such that the altered protein has a 90% homology (i.e., similarity) to MANF, they have to come to MANF and license it. That is unbelievably valuable. That is why I refuse to sell this stock and why I think anyone that is not in the stock and anyone looking to flip it will come to regret it.
Ties between GDNF, MANF and Hermo Pharma
(1) Hermo Pharma is currently working on CDNF, another protein in the trophic factors family
(2) Hermo Pharma is funded by VCs and has $700k in MJFF grants
(3) World reknown Professor Mart Saarma is on the Scientific Advisory Board of Hermo Pharma:http://www.hermopharma.com/about-us/scientific-advisory-board
(4) Mart Saarma was intimately involved with GDNF and is keenly aware of the entire trophic factors family of proteins
(5) Mart Saarma has worked with Professor Steven Gill from Bristol Univ who is now leading GDNF in phase II trials. Prof Gill has developed a new infusion device that allows for much better and more efficient delivery methods: http://www.wobblywilliams.com/gdnf.html
(6) Mart Saarma and Hermo Pharma sued AMBS, challenging their patents in court in Europe on the grounds that their MANF patents cause "an undue burden on anyone trying to test MANF because it covers anything with a 90% homology (ie similarity) to MANF:"; AMBS's patents were upheld in court:
http://m.seekingalpha.com/instablog/167303-jonathan-verenger/1348791-exciting-field-in-cure-for-parkinson-s
(7) It has been shown that MANF performs better than CDNF and GDNF in pre clinical trials.
(8) GDNF was owned by a company purchased for $250 Million during pre-clinical trials.
(9) Neurturin is another trophic factor in phase I that has received $150 Million in funding.
All of the above reasons are why I'm so bullish on this company and why I think there will be much higher prices in store. I believe that a partnership/licensing deal is the most likely outcome. I don't expect a buyout. I think someone will come in initially with a $15 Million funding as well as a licensing deal. The patents that AMBS owns and that were upheld in court are far too valuable. Anyone that wants to work on MANF has to come through AMBS. If anyone alters any of the other proteins (GDNF, CDNF, etc) such that the altered protein has a 90% homology (i.e., similarity) to MANF, they have to come to MANF and license it. That is unbelievably valuable. That is why I refuse to sell this stock and why I think anyone that is not in the stock and anyone looking to flip it will come to regret it.
References on Mart Saarma
http://www.google.com/search?client=safari&rls=en&q=mart+saarma+gdnf&ie=UTF-8&oe=UTF-8
**Ties between GDNF, MANF and Hermo Pharma**
(1) Hermo Pharma is currently working on CDNF, another protein in the trophic factors family
(2) Hermo Pharma is funded by VCs and has $700k in MJFF grants
(3) World reknown Professor Mart Saarma is on the Scientific Advisory Board of Hermo Pharma:http://www.hermopharma.com/about-us/scientific-advisory-board
(4) Mart Saarma was intimately involved with GDNF and is keenly aware of the entire trophic factors family of proteins
(5) Mart Saarma has worked with Professor Steven Gill from Bristol Univ who is now leading GDNF in phase II trials. Prof Gill has developed a new infusion device that allows for much better and more efficient delivery methods: http://www.wobblywilliams.com/gdnf.html
(6) Mart Saarma and Hermo Pharma sued AMBS, challenging their patents in court in Europe on the grounds that their MANF patents cause "an undue burden on anyone trying to test MANF because it covers anything with a 90% homology (ie similarity) to MANF:"; AMBS's patents were upheld in court:
http://m.seekingalpha.com/instablog/167303-jonathan-verenger/1348791-exciting-field-in-cure-for-parkinson-s
(7) It has been shown that MANF performs better than CDNF and GDNF in pre clinical trials.
(8) GDNF was owned by a company purchased for $250 Million during pre-clinical trials.
(9) Neurturin is another trophic factor in phase I that has received $150 Million in funding.
All of the above reasons are why I'm so bullish on this company and why I think there will be much higher prices in store. I believe that a partnership/licensing deal is the most likely outcome. I don't expect a buyout. I think someone will come in initially with a $15 Million funding as well as a licensing deal. The patents that AMBS owns and that were upheld in court are far too valuable. Anyone that wants to work on MANF has to come through AMBS. If anyone alters any of the other proteins (GDNF, CDNF, etc) such that the altered protein has a 90% homology (i.e., similarity) to MANF, they have to come to MANF and license it. That is unbelievably valuable. That is why I refuse to sell this stock and why I think anyone that is not in the stock and anyone looking to flip it will come to regret it.
References on Mart Saarma
http://www.google.com/search?client=safari&rls=en&q=mart+saarma+gdnf&ie=UTF-8&oe=UTF-8
**Ties between GDNF, MANF and Hermo Pharma**
(1) Hermo Pharma is currently working on CDNF, another protein in the trophic factors family
(2) Hermo Pharma is funded by VCs and has $700k in MJFF grants
(3) World reknown Professor Mart Saarma is on the Scientific Advisory Board of Hermo Pharma:http://www.hermopharma.com/about-us/scientific-advisory-board
(4) Mart Saarma was intimately involved with GDNF and is keenly aware of the entire trophic factors family of proteins
(5) Mart Saarma has worked with Professor Steven Gill from Bristol Univ who is now leading GDNF in phase II trials. Prof Gill has developed a new infusion device that allows for much better and more efficient delivery methods: http://www.wobblywilliams.com/gdnf.html
(6) Mart Saarma and Hermo Pharma sued AMBS, challenging their patents in court in Europe on the grounds that their MANF patents cause "an undue burden on anyone trying to test MANF because it covers anything with a 90% homology (ie similarity) to MANF:"; AMBS's patents were upheld in court:
http://m.seekingalpha.com/instablog/167303-jonathan-verenger/1348791-exciting-field-in-cure-for-parkinson-s
(7) It has been shown that MANF performs better than CDNF and GDNF in pre clinical trials.
(8) GDNF was owned by a company purchased for $250 Million during pre-clinical trials.
(9) Neurturin is another trophic factor in phase I that has received $150 Million in funding.
All of the above reasons are why I'm so bullish on this company and why I think there will be much higher prices in store. I believe that a partnership/licensing deal is the most likely outcome. I don't expect a buyout. I think someone will come in initially with a $15 Million funding as well as a licensing deal. The patents that AMBS owns and that were upheld in court are far too valuable. Anyone that wants to work on MANF has to come through AMBS. If anyone alters any of the other proteins (GDNF, CDNF, etc) such that the altered protein has a 90% homology (i.e., similarity) to MANF, they have to come to MANF and license it. That is unbelievably valuable. That is why I refuse to sell this stock and why I think anyone that is not in the stock and anyone looking to flip it will come to regret it.
References on Mart Saarma
http://www.google.com/search?client=safari&rls=en&q=mart+saarma+gdnf&ie=UTF-8&oe=UTF-8
Stars are aligned for a move to $0.40+ shortly.
The market cap at $22-3 million is way too small for this company given the facts below. We will continue to go higher much to the chagrin of every naysayer / disbeliever. Whether its people spreading unfounded fears of dilution or the Michael J Fox Foundation not finding the MANF data as positive or the share lockup due to the CUSIP change, people will find any reason to sell. No one can hold because 99.99% of investors are impatient. The patient ones here like smoke_em, aewilliamson, lewsogge and me will make out like bandits here because we know the facts will win out:
+The CSO, John Commissiong, is a world reknown Scientist and former head of Neurotrophic Factors at NIH and professor at world reknown McGill University): https://www.michaeljfox.org/foundation/researchers.php?id=1015 (notice where this link goes to?)
+Money poured into GDNF at same stage of testing (pre clinical which GDNF had worse results than MANF) ~ $250 Million
+GDNF had issues with poor diffusion rates and had issues with binding heparin with high affinity both of which aren't characteristics of MANF
+Money poured into Neurturin, another protein in the class of neurotrophic factors, which is in stage I ~ $150 Million
+Patent protection - upheld in court vs Hermo Pharma, a VC backed and MJFF funded biotech firm
+A partner at Hermo Pharma even admitted that the company's MANF patents cause "an undue burden on anyone trying to test MANF because it covers anything with a 90% homology (ie similarity) to MANF: http://m.seekingalpha.com/instablog/167303-jonathan-verenger/1348791-exciting-field-in-cure-for-parkinson-s
+Founder of Amgen believes it could be the biggest success he has ever seen. He is also presenting alongside the CSO on 1/8/13 in front of a crowd of Pharma companies and VC investors about the commercial opportunities that exist for MANF. I'm thinking that having the co founder of a $70 Billion drug company presenting on the commercial opportunities of your drug will be beneficial but call me crazy
AMBS is an EPIC Stock. EPIC Stocks can be found once every 5 years or so. They go up several hundred fold over the span of 6 to 12 months because their potential is so much greater than the market realized and it collectively comes to an aha moment. Bashers/impatient investors will continue to watch it go higher in disbelief that they sold or never got in when it was staring them right in their eyes.
I've enjoyed your negative commentary since the $0.02 levels. Always a good perspective on things.
Good call. You've been spot on for 6 weeks now...
hehe.
Awesome Presentation:
http://www.onemedplace.com/database/list/cid/13336
Best part > Listen at around 13 minutes.
One thing that I see happening is talk about pursuing Orphan Drug Status on a variety of diseases that MANF can help with. Dr. Rubinfeld mentioned this several times.
I agree except this one seems balanced. Plus I love that he got an interview with the partner of the company that challenged AMBS's patents...they wouldn't have challenged them if they didn't believe they were important.
http://m.seekingalpha.com/instablog/167303-jonathan-verenger/1348791-exciting-field-in-cure-for-parkinson-s
Stars are aligned for a move to $0.40+ shortly. The market cap at $23 million is way too small for this company given the facts below. We will continue to go higher much to the chagrin of every naysayer / disbeliever.
We can only lead the horse to water. We can't make it drink. We get a little selling in a 2 hour span on thursday after a 500% move up and all of the sudden its dilution and the Michael j fox foundation thinks MANF data isn't positive. Funny stuff. The patient ones here like smoke_em, aewilliamson, lewsogge and me will make out like bandits here because we know the facts will win out:
+The CSO, John Commissiong, is a world reknown Scientist and former head of Neurotrophic Factors at NIH and professor at world reknown McGill University): https://www.michaeljfox.org/foundation/researchers.php?id=1015 (notice where this link goes to?)
+Money poured into GDNF at same stage of testing (pre clinical which GDNF had worse results than MANF) ~ $250 Million
+GDNF had issues with poor diffusion rates and had issues with binding heparin with high affinity both of which aren't characteristics of MANF
+Money poured into Neurturin, another protein in the class of neurotrophic factors, which is in stage I ~ $150 Million
+Patent protection - upheld in court vs Hermo Pharma, a VC backed and MJFF funded biotech firm
+A partner at Hermo Pharma even admitted that the company's MANF patents cause "an undue burden on anyone trying to test MANF because it covers anything with a 90% homology (ie similarity) to MANF: http://m.seekingalpha.com/instablog/167303-jonathan-verenger/1348791-exciting-field-in-cure-for-parkinson-s
+Founder of Amgen believes it could be the biggest success he has ever seen. He is also presenting alongside the CSO on 1/8/13 in front of a crowd of Pharma companies and VC investors about the commercial opportunities that exist for MANF. I'm thinking that having the co founder of a $70 Billion drug company presenting on the commercial opportunities of your drug will be beneficial but call me crazy
AMBS is an EPIC Stock. EPIC Stocks can be found once every 5 years or so. They go up several hundred fold over the span of 6 to 12 months because their potential is so much greater than the market realized and it collectively comes to an aha moment. For people like us who got in and hold from the .02 to .03 level or below we will net a 20 to 100 bagger. 99.99% of investors lack patience to hold throughout.. The patient ones will make out like bandits. Bashers/impatient investors will continue to watch it go higher in disbelief that they sold or never got in when it was staring them right in their eyes.
We can only lead the horse to water. We can't make it drink. We get a little selling in a 2 hour span after a 500% move up and all of the sudden its dilution and the Michael j fox foundation thinks MANF data isn't positive. Funny stuff. The patient ones here like smoke_em, aewilliamson, lewsogge and me will make out like bandits here because we know the facts will win out:
+CSO is a world reknown Scientist and former head of Neurotrophic Factors at NIH and professor at world reknown McGill University): https://www.michaeljfox.org/foundation/researchers.php?id=1015 (notice where this link goes to?)
+Money poured into GDNF at same stage of testing (which has had worse results than MANF) ~ $250 Million
+GDNF had issues with poor diffusion rates and had issues with binding heparin with high affinity both of which aren't characteristics of MANF
+Money poured into Neurturin, another protein in the class of neurotrophic factors, which is in stage I ~ $150 Million
+Patent protection - upheld in court vs Hermo Pharma, a VC backed and MJFF funded biotech firm
+A partner at Hermo Pharma even admitted that the company's MANF patents cause "an undue burden on anyone trying to test MANF because it covers anything with a 90% homology (ie similarity) to MANF: http://m.seekingalpha.com/instablog/167303-jonathan-verenger/1348791-exciting-field-in-cure-for-parkinson-s
+Founder of Amgen believes it could be the biggest success he has ever seen. He is also presenting alongside the CSO on 1/8/13 in front of a crowd of Pharma companies and VC investors about the commercial opportunities that exist for MANF.
AMBS is an EPIC Stock. EPIC Stocks can be found once every 5 years or so. They go up several hundred fold over the span of 6 to 12 months because their potential is so much greater than the market realized and it collectively comes to an aha moment. For people like us who got in and hold from the .02 to .03 level or below we will net a 20 to 100 bagger. 99.99% of investors lack patience to hold throughout.. The patient ones will make out like bandits. Bashers/impatient investors will continue to watch it go higher in disbelief that they sold or never got in when it was staring them right in their eyes.
Stars are aligned for a move to $0.40+ shortly. The market cap at $23 million is way too small for this company given the above facts. We will continue to go higher much to the chagrin of every naysayer / disbeliever.
Yep anyone down on the stock is most likely hoping it dips. The action yesterday was extremely bullish considering the pullback on Thursday. People that sold on Thursday before the dip got lucky but with the quick snap back they have to be getting a bit anxious now. That's why you see so many negative posters. It would be nice if people actually had some integrity but its a message board and people are able to hide behind their monikers. Doesn't matter in the end because the stock is an epic stock that you only see once every handful of years. It is heading much much higher.
Good post from Yahoo board:
How bout that 8-K? So, in summary, what do we have so far? I won't go into all that has been rehashed....here's a quick primer:
We have a company that is transparent, the CEO "seems" to give a #$%$ about the people that believe in his companies efforts, a symbol change to protect shareholders from the Berlin stock exchange and shorting efforts, a victorious lawsuit upholding their patents (again, if they didn't have anything, why would someone try and take it?), numerous members of the board that are industry experts that specialize in bringing the big guys to the table, a postponed reveal of their test results until a time that it will really matter ie, the Jan 8th conference, and the grand daddy of them all, a measure to protect the shareholders from a hostile bid takeover (that's what it was wasn't it?).....right before they present the said results.
Why would they feel the need to do this if their results would not warrant it? They have something and they know it. Their legal counsel has obviously advised them wisely if the company believes that what they have, others will want. They seem to be positioning themselves in the direction of a huge success.
All this because, they're not sure or the results are mediocre at best? We already know what they have (MANF) works and they must know/believe that it will work in humans. Do you wait until the human trial are complete? What more would you need to see in terms of information to make you believe that they are on to something big? I have yet to see anything (well other than the occasional stupid #$%$ post from a basher) that makes me think that this won't be , as Dr Rubinfeld has stated......"a blockbuster drug".
He is co-presenting it at the conference, is he not? Would he risk his reputation on something he knew wasn't a game changer? Well, of course unless he was really hurting for cash, which I doubt. Lets make this board about the FACTS as we see/find them and just ignore those that have obvious agendas. No need to even comment on them and if ya want to shut them up, just don't comment. If the FACTS change, then lets discuss them, but please, refrain from just throwing out figures/share prices on events that have not happened. People who will be coming to this board, looking for information on the stock will tend to be turned away when they read the usual penny stock jargon, insults and shenanigans. Lets be smart here people and work together to help each other achieve what could be...financial windfalls. Stay informed, and share what you find to be relevant. Peace and good luck.
We can only lead the horse to water. We can't make it drink. We get a little selling in a 2 hour span after a 500% move up and all of the sudden its dilution and the Michael j fox foundation thinks MANF data isn't positive. Funny stuff. The patient ones here like smoke_em, aewilliamson, lewsogge and me will make out like bandits here because we know the facts will win out:
+CSO is a world reknown Scientist and former head of Neurotrophic Factors at NIH and professor at world reknown McGill University): https://www.michaeljfox.org/foundation/researchers.php?id=1015 (notice where this link goes to?)
+Money poured into GDNF at same stage of testing (which has had worse results than MANF) ~ $250 Million
+GDNF had issues with poor diffusion rates and had issues with binding heparin with high affinity both of which aren't characteristics of MANF
+Money poured into Neurturin, another protein in the class of neurotrophic factors, which is in stage I ~ $150 Million
+Patent protection - upheld in court vs Hermo Pharma, a VC backed and MJFF funded biotech firm
+A partner at Hermo Pharma even admitted that the company's MANF patents cause "an undue burden on anyone trying to test MANF because it covers anything with a 90% homology (ie similarity) to MANF: http://m.seekingalpha.com/instablog/167303-jonathan-verenger/1348791-exciting-field-in-cure-for-parkinson-s
+Founder of Amgen believes it could be the biggest success he has ever seen. He is also presenting alongside the CSO on 1/8/13 in front of a crowd of Pharma companies and VC investors about the commercial opportunities that exist for MANF.
AMBS is an EPIC Stock. EPIC Stocks can be found once every 5 years or so. They go up several hundred fold over the span of 6 to 12 months because their potential is so much greater than the market realized and it collectively comes to an aha moment. For people like us who got in and hold from the .02 to .03 level we will net a 20 to 60 bagger. 99.99% of investors lack patience to hold throughout.. The patient ones will make out like bandits. Bashers/impatient investors will continue to watch it go higher in disbelief that they sold or never got in when it was staring them right in their eyes.
Stars are aligned for a move to $0.40+ shortly. The market cap at $23 million is way too small for this company given the above facts. We will continue to go higher much to the chagrin of every naysayer / disbeliever.
Wow - Anyone read the 8-k?
"The Board authorized the adoption of a Rights Agreement in order to protect stockholders from coercive or otherwise unfair takeover tactics"
"the Company is conferring with leading academics and collaborators to confirm various aspects of the data results in order to ensure complete accuracy and transparency. The Company believes confirmation of the results with leaders in the field prior to release to the public is in the best interests of its shareholders."
I wasn't really expecting a buyout to be honest. While GDNF was purchased during pre clinical trials for $250 Million, I'm only using that as a benchmark for valuation of AMBS. MANF is producing better results and delivery methods have improved dramatically since then. Assuming a hefty discount I still think the MANF protein, with patent protection recently upheld in court, would be worth $100 Million. Now we get news that they're instituting a Rights Agreement just ahead of the 1/8/13 presentation which will be done in front of big pharma and VC investors and one of the presenters is the co-Founder of Amgen. This is setting up for an interesting couple of weeks here to say the least.
Again, I think this is an EPIC STOCK - one that comes around only once every 5 years or so. They go up 100 to 300 times from the bottom to the top in a 6 month period and any pullback turns into a buying opportunity. People that try to flip it end up chasing it higher with less and less shares and resort to bashing it on the grounds of phony conspiracy theories about dilutions etc...the patient ones make out like bandits.
AMBS is an EPIC Stock. EPIC Stocks can be found once every 5 years or so. They go up 100 to 300 times their value over the span of 6 months. Bashers come on board and try to knock it down only to watch it put in higher lows throughout the run and leave people without patience sitting in awe as the stock barrels higher. People will try to spin wild webs of fancy like dilution, conspiracy theories as to why they drop suddenly every once in a while, etc. Yet after each minor blip it continues higher. Anyone that sells is left kicking themselves. That's what EPIC stocks do.
For people like me who got in around .025 I will only book a 20 to 40 bagger. But I have patience which 99% of investors lack. The patient ones will make out like bandits.
Stars are aligned for a move to $0.40+ shortly. The market cap at $20 million is way too small for this company given:
+Money poured into GDNF at same stage of testing (which has had worse results than MANF) ~ $250 Million
+Money poured into Neurturin which is in stage I ~ $150 Million
+Patent protection - upheld in court vs Hermo Pharma, a VC backed and MJFF funded biotech firm
+Founder of Amgen believes it could be the biggest success he has ever seen.
AMBS will continue to go higher much to the chagrin of every naysayer / disbeliever.
Awesome Presentation:
http://www.onemedplace.com/database/list/cid/13336
Best part > Listen at around 13 minutes.
We can only lead the horse to water. We can't make it drink. We get a little selling in a 2 hour span after a 500% move up and all of the sudden its dilution. Funny stuff.
AMBS is an EPIC Stock. EPIC Stocks can be found once every 5 years or so. They go up 100 to 300 times their value over the span of 6 months. For people like us who got in and held we will net a 20 to 40 bagger. We have patience which 99.99% of investors lack. The patient ones will make out like bandits. Bashers/impatient investors will continue to watch it go higher in disbelief.
Stars are aligned for a move to $0.40+ shortly. The market cap at $20 million is way too small for this company given:
+Money poured into GDNF at same stage of testing (which has had worse results than MANF) ~ $250 Million
+Money poured into Neurturin which is in stage I ~ $150 Million
+Patent protection - upheld in court vs Hermo Pharma, a VC backed and MJFF funded biotech firm
+Founder of Amgen believes it could be the biggest success he has ever seen.
AMBS will continue to go higher much to the chagrin of every naysayer / disbeliever.
AMBS is an EPIC Stock. EPIC Stocks can be found once every 5 years or so. They go up 100 to 300 times their value over the span of 6 months. Bashers come on board and try to knock it down only to watch it put in higher lows throughout the run and leave people without patience sitting in awe as the stock barrels higher. People will try to spin wild webs of fancy like dilution, conspiracy theories as to why they drop suddenly every once in a while, etc. Yet after each minor blip it continues higher. Anyone that sells is left kicking themselves. That's what EPIC stocks do.
For people like me who got in around .025 I will only book a 20 to 40 bagger. But I have patience which 99% of investors lack. The patient ones will make out like bandits.
Stars are aligned for a move to $0.40+ shortly. The market cap at $20 million is way too small for this company given:
+Money poured into GDNF at same stage of testing (which has had worse results than MANF) ~ $250 Million
+Money poured into Neurturin which is in stage I ~ $150 Million
+Patent protection - upheld in court vs Hermo Pharma, a VC backed and MJFF funded biotech firm
+Founder of Amgen believes it could be the biggest success he has ever seen.
AMBS will continue to go higher much to the chagrin of every naysayer / disbeliever.